8-K: Theravance Biopharma Hits Record YUPELRI Sales, Nears Key Ampreloxetine Data

Theravance Biopharma reported record third-quarter 2025 YUPELRI net sales and achieved non-GAAP breakeven, while advancing its pivotal Phase 3 CYPRESS study for ampreloxetine with topline results expected in Q1 2026.

Summary

• YUPELRI net sales reached an all-time high of $71.4 million in Q3 2025, recognized by Viatris, up 15% year-over-year.
• Customer demand for YUPELRI grew 6% year-over-year, and doses pulled through the hospital channel increased by 29% year-over-year.
• The open-label portion of the pivotal Phase 3 CYPRESS study for ampreloxetine is now complete, with topline results expected in Q1 2026.
• TRELEGY year-to-date global net sales are approximately $2.9 billion, putting the company on track to trigger a $50 million milestone from Royalty Pharma in 2025 (requires approximately $471 million in Q4 2025).
• The company maintains a strong balance sheet with $332.7 million in cash, cash equivalents, and marketable securities, and no debt as of September 30, 2025.
• Total revenue for Q3 2025 was $20.0 million, consisting entirely of Viatris collaboration revenue, an increase of 19% compared to Q3 2024.
• Net income for Q3 2025 was $3.6 million, a significant improvement from a net loss of $12.7 million in Q3 2024, benefiting from a $6.5 million income tax benefit.
• Non-GAAP net income from operations was $2.3 million in Q3 2025, achieving breakeven.
• Full-year 2025 R&D expenses (excluding share-based compensation) are expected to be $32 million to $38 million, and SG&A expenses (excluding share-based compensation) are expected to be $50 million to $60 million.
• Full-year 2025 share-based compensation expenses are expected to be $18 million to $20 million.
• The company expects to remain at similar breakeven non-GAAP net income levels in Q4 2025, excluding one-time items, reflecting sustained operating discipline.
• A Strategic Review Committee, formed on November 12, 2024, continues to evaluate a range of strategic alternatives to further enhance shareholder value.

Sentiment

Score: 8

Explanation: The company reported strong financial results with record YUPELRI sales and achieved non-GAAP breakeven. The pivotal Phase 3 study for ampreloxetine is on track for topline results in Q1 2026, representing a significant near-term catalyst. The balance sheet is strong with substantial cash and no debt, and the company is on track for multiple high-value milestone payments. While SG&A increased, overall financial discipline and pipeline progress are positive.

Positives

• YUPELRI net sales reached an all-time high of $71.4 million in Q3 2025, a 15% year-over-year increase, and achieved record brand profitability.
• Customer demand growth for YUPELRI was 6% year-over-year, and hospital channel doses increased by 29% year-over-year.
• The company is on track to trigger a $25 million milestone for YUPELRI if U.S. net sales exceed $250 million in 2025 (requires approximately $54 million in Q4 2025).
• TRELEGY year-to-date sales of approximately $2.9 billion are on track to trigger a $50 million milestone from Royalty Pharma in 2025.
• A strong balance sheet with $332.7 million in cash, cash equivalents, and marketable securities, and no debt as of September 30, 2025.
• Total revenue for Q3 2025 increased by $3.1 million, or 19%, compared to Q3 2024.
• Net income of $3.6 million in Q3 2025, a significant improvement from a $12.7 million net loss in Q3 2024.
• Achieved non-GAAP breakeven net income from operations of $2.3 million in Q3 2025, compared to a $2.9 million non-GAAP net loss in Q3 2024.
• R&D expenses decreased to $8.1 million in Q3 2025 from $9.3 million in Q3 2024, reflecting continued cost discipline.
• An income tax benefit of $6.5 million in Q3 2025 reflects a favorable true-up related to taxes from the TRELEGY royalty sale.
• Ampreloxetine Phase 3 CYPRESS study enrollment completed in August 2025, with topline results on track for Q1 2026.
• Ampreloxetine has been granted Orphan Drug Designation for symptomatic nOH in MSA patients, indicating a high unmet medical need.
• YUPELRI has intellectual property protection in the U.S. into 2039, providing long-term revenue stability.

Negatives

• Selling, General and Administrative (SG&A) expenses increased to $18.3 million in Q3 2025 from $16.9 million in Q3 2024.
• Excluding the $6.5 million income tax benefit, the third quarter net loss would have been $2.9 million.

Risks

• Factors that could increase the company's cash requirements or expenses beyond its expectations and any factors that could adversely affect its profitability.
• Uncertainty regarding whether the milestone thresholds for YUPELRI and TRELEGY can be achieved.
• Delays or difficulties in commencing, enrolling, or completing clinical studies for product candidates like ampreloxetine.
• The potential that results from clinical or non-clinical studies indicate the company's product candidates or product are unsafe, ineffective, or not differentiated.
• Risks of decisions from regulatory authorities that are unfavorable to the company.
• Dependence on third parties to conduct clinical studies.
• Delays or failure to achieve and maintain regulatory approvals for product candidates.
• Risks of collaborating with or relying on third parties to discover, develop, manufacture, and commercialize products.
• Risks associated with establishing and maintaining sales, marketing, and distribution capabilities with appropriate technical expertise and supporting infrastructure.
• The ability of the company to protect and to enforce its intellectual property rights.
• Volatility and fluctuations in the trading price and volume of the company's shares.
• General economic and market conditions.

Future Outlook

The company anticipates maintaining non-GAAP breakeven net income from operations in Q4 2025, excluding one-time items, reflecting sustained operating discipline. Topline results for the pivotal Phase 3 CYPRESS study of ampreloxetine are expected in Q1 2026, with plans for an expedited NDA submission and a request for priority FDA review if data are supportive. The company is on track to achieve a $25 million YUPELRI sales milestone and a $50 million TRELEGY sales milestone in 2025, and an additional $100 million TRELEGY milestone in 2026.

Management Comments

• "Theravance delivered strong results in the third quarter, highlighted by record YUPELRI net sales and the achievement of non-GAAP breakeven, underscoring our commitment to financial and operational discipline." Rick E Winningham, Chief Executive Officer.
• "We continue to advance ampreloxetine toward topline results from the pivotal Phase 3 CYPRESS study in the first quarter of 2026. Backed by a strong balance sheet, durable YUPELRI cash flow, and multiple high-value milestones ahead, we approach this important catalyst from a position of strength—ready to deliver results that could transform the standard of care for multiple system atrophy patients and drive lasting value for patients and shareholders." Rick E Winningham, Chief Executive Officer.

Industry Context

The strong performance of YUPELRI in the COPD market, particularly with increased hospital channel pull-through, indicates continued adoption of nebulized LAMA therapies. The advancement of ampreloxetine for symptomatic nOH in MSA patients addresses a significant unmet medical need in a rare disease, positioning Theravance Biopharma as a potential leader in precision medicine for autonomic disorders. The company's ability to generate substantial cash flow from existing products like YUPELRI and TRELEGY royalties provides a solid financial foundation to support its late-stage pipeline development, a common strategy for biopharma companies de-risking R&D.

Comparison to Industry Standards

• YUPELRI's 15% year-over-year net sales growth and 29% year-over-year hospital dose growth demonstrate strong market penetration and demand in the COPD segment, outperforming many mature pharmaceutical products.
• The progress of ampreloxetine, an investigational selective norepinephrine reuptake inhibitor, for symptomatic nOH in MSA patients, positions it in a niche market with high unmet need, similar to other orphan drug developments by companies like BioMarin Pharmaceutical Inc. or Sarepta Therapeutics, Inc., which target rare diseases with limited treatment options.
• The achievement of non-GAAP breakeven in Q3 2025, coupled with a strong cash position of $332.7 million and no debt, indicates robust financial management, which is favorable compared to many smaller biotechs that often rely heavily on external financing for pipeline development.
• TRELEGY's global net sales growth of 24% in Q3 2025 and 13% year-to-date, as reported by GSK, reflects strong market acceptance for triple therapy in COPD/asthma, a segment where products like AstraZeneca's Breztri Aerosphere also compete.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased value through strong financial performance, milestone achievements, and the Strategic Review Committee's efforts to enhance shareholder value. Positive clinical trial results for ampreloxetine could significantly boost stock value.
• Patients (COPD): Continued availability and growth of YUPELRI, an effective maintenance treatment.
• Patients (MSA with nOH): Potential for a new, effective treatment (ampreloxetine) if Phase 3 results are positive, addressing a high unmet medical need.
• Employees: Continued operational discipline and potential for growth with successful pipeline development.
• Viatris (Partner): Continued strong collaboration and shared profits from YUPELRI.
• Royalty Pharma (Partner): Potential for significant milestone payments based on TRELEGY sales.

Next Steps

• Host a virtual Key Opinion Leader (KOL) event for investors on December 8, 2025, focusing on ampreloxetine.
• Anticipate topline results from the pivotal Phase 3 CYPRESS study of ampreloxetine in Q1 2026.
• Prepare for an expedited NDA submission and request priority FDA review for ampreloxetine if data are supportive.
• Continue to evaluate strategic alternatives to enhance shareholder value through the Strategic Review Committee.
• Achieve approximately $54 million in YUPELRI net sales in Q4 2025 to trigger a $25 million milestone.
• Achieve approximately $471 million in TRELEGY global net sales in Q4 2025 to trigger a $50 million milestone.
• Achieve approximately $3.5 billion in TRELEGY global net sales in FY 2026 to trigger a $100 million milestone.

Key Dates

Recommendation

Theravance Biopharma demonstrates strong operational and financial discipline, achieving non-GAAP breakeven and record YUPELRI sales. The company possesses a robust balance sheet with significant cash and no debt, providing stability. The upcoming Q1 2026 topline results for ampreloxetine's pivotal Phase 3 CYPRESS study represent a major, high-impact catalyst for a rare disease with significant unmet need. Successful data could lead to expedited FDA review and substantial market opportunity. The company is also on track to receive multiple high-value milestone payments from its TRELEGY and YUPELRI collaborations, further strengthening its financial position. The combination of a growing commercial product, a de-risked late-stage pipeline asset, and a strong financial foundation makes TBPH an attractive investment.

Keywords

Theravance Biopharma, TBPH, YUPELRI, revefenacin, COPD, Ampreloxetine, neurogenic orthostatic hypotension, nOH, Multiple System Atrophy, MSA, CYPRESS study, TRELEGY, financial results, Q3 2025, biopharma, pharmaceuticals, clinical trials, milestone payments, Orphan Drug Designation, SEC filing, 8-K